Evidence map›Paper›PMID 41343276›Full record

ArticleCell reports2025

Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV.

Ahlam N Qerqez, Katja Hoffmann, Alison G Lee, Sumit Pareek, Kelli Hager, Akaash K Mishra, George Delidakis, Kirsten Bentley, Lauren Kerr-Jones, Mica Cabrera and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. A viral glycoprotein targets IgGEMBO molecular medicine · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Ahlam N QerqezDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA. Electronic address: ahlam.qerqez@gmail.com.
Katja HoffmannInstitute of Virology, University Medical Center, and Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany. Electronic address: katja.hoffmann@uniklinik-freiburg.de.
Alison G LeeDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Sumit PareekDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Kelli HagerDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Akaash K MishraDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
George DelidakisDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Kirsten BentleyDivision of Infection and Immunology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Lauren Kerr-JonesDivision of Infection and Immunology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Mica CabreraDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Truong NguyenDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Rebecca L GöttlerInstitute of Virology, University Medical Center, and Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
Amjad ChowdhuryDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Philipp L KolbInstitute of Virology, University Medical Center, and Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
Hartmut HengelInstitute of Virology, University Medical Center, and Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
George GeorgiouDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA; Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA; LaMontaigne Center for Infectious Diseases, University of Texas at Austin, Austin, TX 78712, USA.
Jason S McLellanDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA; LaMontaigne Center for Infectious Diseases, University of Texas at Austin, Austin, TX 78712, USA.
Richard J StantonDivision of Infection and Immunology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Annalee W NguyenDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Jennifer A MaynardDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA; LaMontaigne Center for Infectious Diseases, University of Texas at Austin, Austin, TX 78712, USA. Electronic address: maynard@che.utexas.edu.

Funding

The role of cell, antigen, and antibody, in controlling virus infection through Fc-dependent mechanismsR01AI186964 · NIAID · CARDIFF UNIVERSITY · PI Ceri Fielding, Jordan Scott Orange · 2025 to 2026
$626k
Engineering potent antibodies against human cytomegalovirusR21AI181328 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI MAYNARD, JENNIFER A · 2024 to 2025
$405k
NIAID NIH HHS R01 AI186964NIAID NIH HHS R21 AI181328Wellcome Trust
6 · The paper itself

Abstract

Antibodies binding cell-surface antigens to activate cellular immunity are an important mechanism of anti-viral protection, yet antibodies targeting cells infected by human cytomegalovirus (HCMV) exhibit limited efficacy. This is due to HCMV immune evasion mechanisms, including viral receptors (vFcγRs) that bind human immunoglobulin G Fc domains to inhibit host Fcγ receptor activation and impair Fc-mediated immune functions. Here, we biochemically characterize two conserved vFcγRs, gp34 and gp68, and map their Fc binding sites. We then engineer Fc variants to retain binding to host Fc receptors CD16A and FcRn but exhibit markedly reduced gp34/gp68 interactions. Antibodies targeting the gB fusogen with engineered Fc domains are not internalized by infected cells, mediate enhanced immune cell activation, and limit viral spread in HCMV-infected fibroblasts more effectively than antibodies with wild-type Fc. This work demonstrates a strategy to enhance therapeutic antibody control of HCMV infections and other herpesvirus infections with similar immune-evasion mechanisms.

Indexed as

CytomegalovirusImmunoglobulin GKiller Cells, NaturalLymphocyte ActivationReceptors, FcAntibodies, ViralCytomegalovirus InfectionsFibroblastsHistocompatibility Antigens Class IHumansImmunoglobulin Fc FragmentsProtein BindingReceptors, IgGAntibodies, ViralFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin Fc FragmentsImmunoglobulin GReceptors, FcReceptors, IgGCP: immunology

Identifiers

PMID41343276
PMCPMC12831531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.